First Phosphate Corp revealed that it had bolstered its team by appointing industry veteran Garry Siskos as the company’s chief operating officer (COO) and finance head, while outgoing CFO Bennett Kurtz moves into the role of chief administrative officer (CAO).
The Canadian company, which is focused on extracting and refining advanced phosphate material for the LFP battery industry, also announced that Gilles Laverdière has been appointed as its new chief geologist.
T Stamp Inc (NASDAQ:IDAI, EURONEXT:AIID), doing business as Trust Stamp, has received a Notice of Allowance for an additional patent by the United States Patent and Trademark Office (USPTO) related to its AI-powered, tokenized-identity products, the company announced.
The patent, titled “Systems and processes for lossy biometric representation," expands the IP protection around the company’s biometric hashing technology used for subject identity verification.
Delivra Health Brands Inc. (TSX-V:DHB) has reported positive adjusted underlying earnings (EBITDA) for a second consecutive quarter and told investors it expects the trend to continue.
The Vancouver-based company, whose brands include LivRelief and Dream Water, reported third-quarter net revenue of $2.35 million, up from $2.34 million in 3Q 2022, supported by higher sales of Dream Water in the US to international distributors.
C3 Metals Inc (TSX-V:CCCM, OTC:CARCF) said an initial Mineral Resource estimate for the Montana de Cobre Zone (MCZ) on its 100%-owned Jasperoide Project in southern Peru has shown measured & indicated mineral resources of 51.9 million tonnes (Mt) at 0.50% total copper and 0.20 grams per ton (g/t) gold for 569.1 million pounds of copper and 326,800 ounces of gold.
In the Measured Mineral Resources category, there was 28.6Mt at 0.60% total copper, 0.24 g/t gold for 380.0 million pounds of copper and 218,200 ounces of gold, while in the Indicated Mineral Resources category, the figures were 23.3Mt at 0.37% total copper, 0.15 g/t gold for 189.1 million pounds of copper and 108,600 ounces of gold, the junior minerals exploration company said.
IXICO PLC (AIM:IXI, OTC:PHYOF) said it is on track to achieve its full-year guidance and expects revenue to increase in the second half and next year as it transitions to a higher proportion of early-phase clinical trials.
Results for the neuroscience analytics specialist’s half year to 31 March 2023 showed an order book of £13.3mln, up from £12.6mln a year earlier and with £11.6mln worth of contracts signed in the last 12 months.
Bradda Head Lithium Limited (AIM:BHL, OTCQB:BHLIF, TSX-V:BHLI) said assay results from the first five holes of the 2023 Basin East Extension (BEE) drill programme in Arizona included the highest grades seen so far across the whole deposit.
The junior added the results confirm that lithium-bearing clay continues and thickens to the west, northwest and north into its BEE lease, a trend expected to lead to a significant resource expansion in the second half of the year.
Accesso Technology Group PLC (AIM:ACSO, OTC:LOQPF) has launched a new point-of-sale (PoS) platform based on intellectual property (IP) acquired last year.
Named ‘accesso Freedom’, it is the first tier-one restaurant and retail solution designed specifically for the cloud, the company said, aimed at clients operating multiple restaurant and retail venues, including theme parks and attractions, ski areas, cultural venues, resorts and casinos.
Cyprium Metals Ltd (ASX:CYM, OTC:CYPMF) has sought to optimise its development and financing strategy for the Nifty Copper Project in Western Australia with the appointment of two industry veterans, Clive Donner and Milan Jerkovic, to the executive team.
The Nifty Project is a brownfield copper mine that Cyprium intends to revitalise with its proprietary copper oxide Heap Leach SX-EW extraction methods, offering higher grades with lower costs and environmental impact.
Tiziana Life Sciences Ltd has said it is now participating on the new Webull Corporate Communication services platform. The Tiziana portal on the Webull platform will help provide the company with a direct line of communication with its shareholders while providing Tiziana's followers with instant notifications regarding corporate content like company news, earnings reports, investor presentations, and more. "We're excited to participate on Webull’s mobile-first brokerage platform with a unique community-driven experience," said Tiziana’s interim CEO, founder and chairman, Gabriel Cerrone. “The Webull platform will enable Tiziana to take advantage of a convenient and efficient digital communications channel to reach the platform of active investors while also allowing us to easily share content with them in real-time.”
Atossa Therapeutics has entered an agreement with a contract development and manufacturing organization, Societal CDMO, which will provide a range of its Clinical Trial Services (CTS) offerings focused on Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen. The agreement spans a range of activities including analytical method transfer/development and validation, cleaning verification method validation, manufacturing of multiple R&D engineering batches, and stability testing of the R&D engineering batches. “Societal’s demonstrated expertise in the technology transfer of established drug products, along with our long track record of successfully formulating and manufacturing innovative small molecules, positions us well to align with Atossa and support the ongoing clinical development of the company’s proprietary oral formulation of (Z)-endoxifen. We are eager to initiate this important work and deliver exceptional results for Atossa,” said David Enloe, chief executive officer of Societal CDMO in a statement.
Genprex Inc has released a new video in which the company's chief medical officer, Dr Mark Berger discusses the recently presented positive preclinical data for the NPRL2 gene by Genprex's research collaborators. The data were presented at the 2023 American Association of Cancer Research (AACR) annual meeting. "The study utilized the same delivery platform that Genprex uses with our REQORSA product candidate but with a different tumor suppressor gene," said Dr Berger. "The whole point of our oncology program is to identify tumor suppressor genes, which are systematically deleted during cancer development, and then re-express the tumor suppressor genes in cancers. This process has shown preclinically that it can achieve strong efficacy and is currently being evaluated in Phase 1/2 clinical trials of REQORSA. Now researchers have replicated that process in in vitro studies with the NPRL2 gene, which we believe is validation that ONCOPREX as a platform may be used with multiple tumor suppressor genes to address multiple types of cancer." To watch the video, interested parties can visit Genprex's website at https://www.genprex.com/videos/.
ImagineAR is conducting a private placement to offer up to 13,030,303 units at a price of $0.033 per unit, aiming to generate gross proceeds of around $430,000. Each unit will consist of one common share and one non-transferable common share purchase warrant. The warrant allows the holder to purchase an additional common share for $0.05 within a period of thirty-six months after the placement closes. The funds raised will be utilized by ImagineAR to improve its SDK technology, provide sales and marketing support, and develop proof of concept immersive AR activations with AI integration.
Predictive Oncology Inc's Chief Business Officer, Pamela Bush, will be presenting at the 2023 BIO International Convention in Boston on June 5, 2023. The presentation will focus on the significance of addressing patient heterogeneity in drug discovery and the benefits of using active machine learning in the process. Other members of Predictive Oncology's scientific and business leadership teams will join Dr. Bush to discuss the company's comprehensive range of drug discovery solutions, including their biologics capabilities for optimized drug formulation. The Predictive Oncology team will also be participating in partnering meetings and will be available for discussions throughout the conference. Attendees are invited to visit Booth 135 during the exhibitor hospitality reception to meet Dr. Larry DeLucas, a former NASA astronaut and the current SVP of Biologics at Predictive Oncology.
Perimeter Medical Imaging AI Inc announced that Anthony Holler has resigned as a director of the company, effective immediately, for personal reasons. "We are grateful for Dr. Holler's many contributions to Perimeter over the years during his tenure on the Board – including his service as Chair from 2019 to 2022,” Jeremy Sobotta, Perimeter's CEO said. “On behalf of the Perimeter team and Board, I thank Dr. Holler for his commitment to Perimeter and wish him all the best in his future endeavors."
NorthWest Copper Corp. has announced that it has been notified by a shareholder about their intention to propose a slate of six dissident nominees for the company's Board of Directors at the upcoming annual general meeting of shareholders. The company is currently reviewing the submission and will provide a response in the future, assuring shareholders that there is no immediate action required from them. NorthWest Copper has enlisted Norton Rose Fulbright Canada LLP as legal counsel, Kingsdale Advisors as a strategic shareholder advisor, and Longview Communications and Public Affairs as their communications advisor.
Crestview Exploration Inc told investors it has closed the second tranche of its non-brokered private placement by issuing 1,460,000 units at $0.105 per unit, for aggregate proceeds of $153,300. Each unit consists of one common share and one share purchase warrant. The Calgary-based exploration company said that it plans to use the proceeds for permitting and other drilling preparatory work, and for general corporate purposes. The firm said each warrant is exercisable into one common share at $0.20 for a term of two years from the date of issuance. Crestview will pay $12,264 in cash and issue 116,800 warrants as compensation to qualified finders. Each warrant is exercisable at $0.20 for a term of two years from the date of issuance. Also, in conjunction with this closing and subject to approval by the Canadian Securities Exchange, the company said it is issuing 482,250 units, on the same terms as the Offering, to GoldPlay LLC, in respect of the Minimum Advanced Royalty Payments for its Divide and Castile projects.
Cloud DX said it will report its first quarter results on May 29, 2023. On the same day at 2pm Eastern Time, the company’s CEO Robert Kaul will host an earnings call to discuss Cloud DX’s financial results to March 31, 2023, as well as further progress towards its strategic goals. “We will also address the status of recent financing activities, acceleration of sales in 2023 and continued evidence of patient and provider satisfaction," Kaul said. Investors can register for the earnings call at: https://us06web.zoom.us/webinar/register/WN_vreHIIw1TnevJN6MpxHUew#/registration.